Health insurance is big business, according to revenue reports from major players in the space. In fact, the five largest conglomerates in healthcare and pharmaceuticals are on track to outpace revenues of the five preeminent technology companies, according to Axios.

Medicare and Medicaid prices have grown at a slower pace than the private market, according to an analysis from the Urban Institute.

Oregon lawmakers are “taking another pass” at universal healthcare for the residents of state, according to a new report by The Register Guard. If SB 770 is passed, it will create a committee that would “design, implement and run a state health insurance plan.” 

Johnson & Johnson (J&J) will provide the list price of its prescription drugs in television advertisements starting in late March. The company will be the first manufacturer to take such a step, according to The New York Times.

As the rising drug price issue has taken hold of the healthcare debate in the U.S., Democrats in Congress have introduced a bill that would allow Medicare to negotiate drug prices. 

This exemption of certain unclassified medical devices from 510(k) requirements aims to achieve two goals: decrease regulatory burdens on the medical device industry and reduce costs required to comply with federal regulations, while allowing patients continued access to medical devices.

The price for a drug that treats Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder that impacts strength and impairs walking, went from cost-free to the price of a house—$375,000 to be exact. 

The American Society of Radiologic Technologists (ASRT) has shown support for new licensure bills introduced in Missouri and Oklahoma.